Advertisement
New Zealand markets open in 7 hours 58 minutes
  • NZX 50

    11,867.29
    +310.09 (+2.68%)
     
  • NZD/USD

    0.6176
    +0.0030 (+0.49%)
     
  • ALL ORDS

    8,024.10
    +53.30 (+0.67%)
     
  • OIL

    75.15
    -1.84 (-2.39%)
     
  • GOLD

    2,352.00
    +6.20 (+0.26%)
     

Swedish Growth Leaders With High Insider Stakes In May 2024

As global markets show signs of stabilization and growth, particularly with easing inflation concerns, Sweden's market environment presents a unique landscape for investors interested in growth companies. High insider ownership in Swedish companies can signal strong confidence in the company's future prospects from those who know it best.

Top 10 Growth Companies With High Insider Ownership In Sweden

Name

Insider Ownership

Earnings Growth

CTT Systems (OM:CTT)

16.9%

21.6%

Spago Nanomedical (OM:SPAGO)

16.1%

52.1%

BioArctic (OM:BIOA B)

35.1%

63.6%

Calliditas Therapeutics (OM:CALTX)

11.6%

49.9%

InCoax Networks (OM:INCOAX)

14.9%

104.9%

KebNi (OM:KEBNI B)

37.8%

90.4%

Egetis Therapeutics (OM:EGTX)

17.6%

98.4%

Yubico (OM:YUBICO)

37.5%

43%

SaveLend Group (OM:YIELD)

24.8%

106.8%

OrganoClick (OM:ORGC)

23%

103.3%

Click here to see the full list of 82 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.

ADVERTISEMENT

We're going to check out a few of the best picks from our screener tool.

BioArctic

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ), based in Sweden, focuses on developing biological drugs for central nervous system disorders and has a market capitalization of approximately SEK 20.33 billion.

Operations: BioArctic's revenue is generated from the development of biological drugs targeting central nervous system disorders.

Insider Ownership: 35.1%

Return On Equity Forecast: 31% (2027 estimate)

BioArctic, a Swedish biopharmaceutical company, has seen a significant decline in sales and profits as reported in its latest quarterly results. However, the company is poised for recovery with expected revenue growth of 48.5% per year and becoming profitable within three years. This growth is bolstered by strategic alliances, like the recent one with Eisai to develop Alzheimer's treatments using BioArctic’s BrainTransporter™ technology. Despite current underperformance, analysts predict a substantial price increase due to these developments and undervaluation compared to fair value estimates.

OM:BIOA B Ownership Breakdown as at May 2024
OM:BIOA B Ownership Breakdown as at May 2024

Fortnox

Simply Wall St Growth Rating: ★★★★★☆

Overview: Fortnox AB (publ) offers financial and administrative software solutions for small and medium-sized businesses, accounting firms, and organizations, with a market capitalization of approximately SEK 41.79 billion.

Operations: The company generates its revenue primarily from Core Products (SEK 698 million), followed by Entrepreneurship (SEK 356 million), The Agency (SEK 327 million), Money (SEK 232 million), and Marketplaces (SEK 150 million).

Insider Ownership: 21%

Return On Equity Forecast: 33% (2027 estimate)

Fortnox, a Swedish software company, reported strong first-quarter earnings with significant year-over-year growth in sales and net income. This performance is underpinned by robust revenue and profit forecasts that exceed market averages, expected to continue over the next three years. Insider activities reflect confidence, showing more buying than selling recently, though not in large volumes. The company's high forecasted Return on Equity suggests efficient use of shareholder funds, aligning with its growth trajectory and high insider ownership.

OM:FNOX Ownership Breakdown as at May 2024
OM:FNOX Ownership Breakdown as at May 2024

AB Sagax

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AB Sagax (publ) is a property company with operations across Sweden, Finland, France, Benelux, Spain, Germany, and other European countries, boasting a market capitalization of approximately SEK 103.84 billion.

Operations: The company generates its revenue primarily from real estate rentals, amounting to SEK 4.47 billion.

Insider Ownership: 28.3%

Return On Equity Forecast: N/A (2027 estimate)

AB Sagax, despite its challenges with debt coverage and shareholder dilution over the past year, remains a focal point due to its robust earnings growth. The company's earnings have surged by 53.3% in the past year and are expected to grow by 33.75% annually over the next three years, outpacing the Swedish market's average. However, revenue growth projections are modest at 9.3% per year. Recent dividends affirm financial health with a significant increase for shareholders approved recently.

OM:SAGA A Earnings and Revenue Growth as at May 2024
OM:SAGA A Earnings and Revenue Growth as at May 2024

Next Steps

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include OM:BIOA B OM:FNOX and OM:SAGA A.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com